About
Investors

Leading a transformational approach to cell and gene therapies for diseases of the skin and connective tissue

Fibrocell is a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue. The Company is utilizing its proprietary autologous fibroblast technology to develop personalized biologics that target the underlying cause of disease. Fibrocell’s pipeline of localized gene therapy candidates include FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a life-threatening genetic disorder diagnosed in infancy with no cure or treatment approved by the U.S. Food and Drug Administration. Fibrocell is also developing FCX-013 for the treatment of moderate to severe localized scleroderma. For more information, visit www.fibrocell.com or follow us on Twitter at @Fibrocell.


Stock Quote



Recent Happenings


Our News and Events

    Press Release

June 04, 2019 1:00 p.m. ET

2019 BIO International Convention

View Event
    Event



E-mail Alerts

Sign up to receive e-mail alerts whenever new information posts to the Fibrocell Science site.Fibrocell Science





Forward-Looking Statements

This website contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Fibrocell’s future operations, financial performance, financial position, prospects, strategies and objectives and other future events. In some cases, you can identify forward-looking statements by words such as “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “scheduled” and similar expressions, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based upon Fibrocell’s current expectations, intentions and assumptions regarding future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of Fibrocell’s control, that could cause actual results to differ materially and adversely from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties and delays relating to the initiation, enrollment and completion of clinical trials; whether clinical trial results will validate and support the safety and efficacy of Fibrocell’s product candidates; the outcome of regulatory review of Fibrocell’s product candidates; unanticipated or excess costs relating to the development of Fibrocell’s gene therapy product candidates; Fibrocell’s ability to obtain additional capital to continue to fund operations; Fibrocell’s ability to maintain its collaborations with Intrexon and Castle Creek Pharmaceuticals; Castle Creek Pharmaceuticals’ ability to successfully commercialize FCX-007, if approved; and the other factors discussed under the caption “Item 1A. Risk Factors” in Fibrocell’s most recent annual report on Form 10-K and its most recent quarterly report on Form 10-Q, which are available in “SEC Filings” under the “Investors” section of this website. Additionally, other unknown, unidentified or unpredictable factors could also materially and adversely impact actual results. As a result, you should not place undue reliance on forward-looking statements.

The forward-looking statements contained on this website represent Fibrocell’s views only as of "05/29/19" (or such earlier date on which it was made). While Fibrocell may update certain forward-looking statements from time to time, it specifically disclaims any obligation to do so, whether as a result of new information, future developments or otherwise. While Fibrocell may update certain forward-looking statements from time to time, it specifically disclaims any obligation to do so, whether as a result of new information, future developments or otherwise.




Printer Friendly Version E-mail this page RSS E-mail Alerts Download Financial Tear Sheet